A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

• DOI: 10.1186/s12967-020-02407-8
• Publication Date: 2020-06-12T06:02:48Z
• Authors: Mi Jian; Li Ren; Guodong He; Qi Lin; Wentao Tang; Yijiao Chen; Jingwen Chen; Tianyu Liu; Meiling Ji; Ye Wei; Wenju Chang; Jianmin Xu
• Keywords: 0301 basic medicine; Research; Liver Neoplasms; R; Colorectal cancer; Liver Transplantation; 3. Good health; Organoids; Liver metastases; Mice; 03 medical and health sciences; Pharmaceutical Preparations; Living Donors; Medicine; Animals; Heterografts; Humans; Animal model; Colorectal Neoplasms

Abstract Backgrounds Cancer-related mortality in patients with colorectal cancer (CRC) is predominantly caused by development of colorectal liver metastases (CLMs). How to screen the sensitive chemotherapy and targeted therapy is the key element to improve the prognosis of CLMs patients. The study aims to develop patient-derived organoids-based xenografted liver metastases (PDOX-LM) model of CRC, to recapitulate the clinical drug response.

Methods We transplanted human CRC primary tumor derived organoids in murine spleen to obtain xenografted liver metastases in murine liver. Immunohistochemistry (IHC) staining, whole-exome and RNA sequencing, and drug response testing were utilized to identify the homogeneity in biological and genetic characteristics, and drug response between the PDOX-LM models and donor liver metastases.

Results We successfully established PDOX-LM models from patients with CLMs. IHC staining showed that positive expression of CEA, Ki67, VEGF, FGFR2 in donor liver metastases were also well preserved in matched xenografted liver metastases. Whole-exon sequencing and transcriptome analysis showed that both xenografted and donor liver metastases were highly concordant in somatic variants (≥ 0.90 frequency of concordance) and co-expression of driver genes (Pearson’s correlation coefficient reach up to 0.99, P = 0.001). Furthermore, drug response testing showed that the PDOX-LM models can closely recapitulated the clinical response to mFOLFOX6 regiments.

Conclusions This PDOX-LM model provides a more convenient and informative platform for preclinical testing of individual tumors by retaining the histologic and genetic features of donor liver metastases. This technology holds great promise to predict treatment sensitivity for patients with CLMs undergoing chemotherapy.